Your browser doesn't support javascript.
loading
[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription.
Kaanders, Johannes H A M; Bussink, Johan; Aarntzen, Erik H J G; Braam, Pètra; Rütten, Heidi; van der Maazen, Richard W M; Verheij, Marcel; van den Bosch, Sven.
Affiliation
  • Kaanders JHAM; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.. Electronic address: j.kaanders@radboudumc.nl.
  • Bussink J; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
  • Aarntzen EHJG; Department of Medical Imaging, Radboud university medical center, Nijmegen, The Netherlands.
  • Braam P; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
  • Rütten H; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
  • van der Maazen RWM; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
  • Verheij M; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
  • van den Bosch S; Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands.
Semin Radiat Oncol ; 33(3): 287-297, 2023 07.
Article in En | MEDLINE | ID: mdl-37331783
ABSTRACT
PET imaging with 2'-deoxy-2'-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluorodeoxyglucose F18 / Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: Semin Radiat Oncol Journal subject: NEOPLASIAS / RADIOLOGIA Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fluorodeoxyglucose F18 / Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: Semin Radiat Oncol Journal subject: NEOPLASIAS / RADIOLOGIA Year: 2023 Document type: Article